Catalyst Pharmaceuticals (NASDAQ:CPRX) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Share on StockTwits

Catalyst Pharmaceuticals (NASDAQ:CPRX) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.07, Bloomberg Earnings reports. The firm had revenue of $28.84 million for the quarter, compared to the consensus estimate of $17.99 million. The firm’s revenue was up 2883900.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.06) EPS.

CPRX traded up $0.08 during trading on Wednesday, reaching $5.13. 1,394,736 shares of the company were exchanged, compared to its average volume of 1,865,701. The company has a 50-day simple moving average of $4.24. The stock has a market cap of $518.36 million, a P/E ratio of -15.55 and a beta of 2.60. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.08. Catalyst Pharmaceuticals has a 12-month low of $1.85 and a 12-month high of $6.16.

CPRX has been the subject of several research reports. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a research note on Wednesday, July 31st. HC Wainwright set a $9.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 14th. BidaskClub upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. ValuEngine cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $10.00 price objective on shares of Catalyst Pharmaceuticals in a report on Tuesday, May 7th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $7.65.

In related news, CEO Patrick J. Mcenany acquired 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were acquired at an average price of $3.23 per share, with a total value of $80,750.00. Following the acquisition, the chief executive officer now owns 4,762,693 shares of the company’s stock, valued at approximately $15,383,498.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in CPRX. Kennedy Capital Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at about $5,099,000. BlackRock Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 11.5% in the 4th quarter. BlackRock Inc. now owns 6,970,873 shares of the biopharmaceutical company’s stock valued at $13,384,000 after acquiring an additional 719,093 shares in the last quarter. EAM Global Investors LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at about $1,409,000. Swiss National Bank purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at about $661,000. Finally, Chicago Equity Partners LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at about $627,000. 59.72% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Featured Story: How Investors Can Profit from Options Trading

Earnings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Smith Shellnut Wilson LLC ADV Raises Stock Holdings in iShares Core S&P Small-Cap ETF
Smith Shellnut Wilson LLC ADV Raises Stock Holdings in iShares Core S&P Small-Cap ETF
Fidelity MSCI Utilities Index ETF  Shares Bought by Smith Shellnut Wilson LLC ADV
Fidelity MSCI Utilities Index ETF Shares Bought by Smith Shellnut Wilson LLC ADV
Prospera Financial Services Inc Reduces Stock Position in First Trust Low Duration Opportunities ETF
Prospera Financial Services Inc Reduces Stock Position in First Trust Low Duration Opportunities ETF
Taconic Capital Advisors LP Increases Stock Position in PG&E Co.
Taconic Capital Advisors LP Increases Stock Position in PG&E Co.
Pimco Municipal Income Fund III  Share Price Passes Above 50-Day Moving Average of $12.56
Pimco Municipal Income Fund III Share Price Passes Above 50-Day Moving Average of $12.56
George Weston  Shares Cross Below 50-Day Moving Average of $79.77
George Weston Shares Cross Below 50-Day Moving Average of $79.77


 
© 2006-2019 Zolmax.